Previously treated cases tested for RR-/MDR-TB (%) in Netherlands
Netherlands: Previously treated cases tested for RR-/MDR-TB was 75.0% in 2024. ▬ Flat
Latest (2024)
75.0%
Change on year
down 15.7%
World rank
123rd
of 180 countries
All-time high
100.0%
in 2006
All-time low
54.0%
in 2020
Years of data
18
2005–2024
Previously treated cases tested for RR-/MDR-TB in Netherlands, 2005–2024
Source: World Health Organization, Global Health Observatory.
Analysis
In 2024, previously treated cases tested for rr-/mdr-tb in Netherlands stood at 75.0%.
Compared with earlier readings it is down 15.7% on the previous year and up 29.3% over ten years.
Over the whole period, previously treated cases tested for rr-/mdr-tb in Netherlands peaked at 100.0% in 2006 and was at its lowest, 54.0%, in 2020.
That places Netherlands 123rd out of 180 countries with data for 2024, putting it in the middle of the range.
Previously treated cases tested for RR-/MDR-TB in Netherlands, year by year
| Year | Value | Change |
|---|---|---|
| 2005 | 68.0% | — |
| 2006 | 100.0% | +47.1% |
| 2008 | 65.0% | -35.0% |
| 2009 | 60.0% | -7.7% |
| 2010 | 69.0% | +15.0% |
| 2011 | 70.0% | +1.4% |
| 2012 | 57.0% | -18.6% |
| 2013 | 68.0% | +19.3% |
| 2014 | 58.0% | -14.7% |
| 2015 | 58.0% | +0.0% |
| 2016 | 56.0% | -3.4% |
| 2017 | 74.0% | +32.1% |
| 2018 | 75.0% | +1.4% |
| 2019 | 87.0% | +16.0% |
| 2020 | 54.0% | -37.9% |
| 2021 | 71.0% | +31.5% |
| 2022 | 89.0% | +25.4% |
| 2024 | 75.0% | -15.7% |
Netherlands compared with similar countries
- Netherlands's 75.0% is below the median for high income countries, which is 83.0%, 90% of the median. (57 countries reporting)
- Netherlands's 75.0% is below the median for Europe & Central Asia, which is 86.0%, 87% of the median. (49 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 73.2% | 60.0% | 100.0% | 4 |
| 2010s | 67.2% | 56.0% | 87.0% | 10 |
| 2020s | 72.2% | 54.0% | 89.0% | 4 |
Countries ranked near Netherlands
More health data for Netherlands
- Un projection of annual infant deaths, annual growth rate -2.44 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 0.1866 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,235 deaths per 1,000 people (2090)
- Number of infants who die before age 1 80 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 0 (2025)
- Population ages 00-04, female, annual growth rate 0.4989 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.0239 units per person (2025)
- Population ages 00-04, male, annual growth rate 0.5005 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2025)
Frequently asked questions
- What is previously treated cases tested for rr-/mdr-tb in Netherlands?
- Previously treated cases tested for rr-/mdr-tb in Netherlands was 75.0% in 2024, according to World Health Organization, Global Health Observatory.
- What is the highest previously treated cases tested for rr-/mdr-tb recorded in Netherlands?
- The highest recorded value was 100.0% in 2006.
- What is the lowest previously treated cases tested for rr-/mdr-tb recorded in Netherlands?
- The lowest recorded value was 54.0% in 2020.
- How does Netherlands rank for previously treated cases tested for rr-/mdr-tb?
- Netherlands ranks 123rd out of 180 countries with data for 2024.
- Is previously treated cases tested for rr-/mdr-tb rising or falling in Netherlands?
- Over the last ten years it is up 29.3%. The long-run trend across the full record is flat.
- Where does this Netherlands data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Previously treated cases tested for RR-/MDR-TB (%). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 18 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).